Superior. Simple. Solventless Full Spectrum CBD!

GET FREE SHIPPING NOW!

"Effortless & hassle-free, We've got you Covered!"

CBD for Dogs: The Complete Evidence-Based Guide (2026)

Dog waiting at vet - CBD natural relief for dogs on the go.

CBD for Dogs: The Complete Evidence-Based Guide (2026)

Last Updated: March 2026 | Based on AVMA 2025 Cannabis Resource Guide

The most comprehensive, research-backed guide to CBD for dogs. Clinical studies, dosing, safety, and what actually works.

Introduction

If you're researching CBD for your dog, you're not alone. Millions of pet owners are turning to cannabidiol (CBD) to support their dogs' wellness, from joint comfort to calm behavior. But with so much conflicting information online, how do you know what actually works?

This comprehensive guide is based on the American Veterinary Medical Association's 2025 Cannabis Resource Guide and peer-reviewed clinical studies. We'll cover exactly what the research shows, how to dose safely, and how to choose quality products.

📚 What You'll Learn:

  • How CBD works in your dog's body (and why dogs respond differently than humans)
  • Clinical study results for arthritis, anxiety, seizures, and skin allergies
  • Research-based dosing guidelines by condition and weight
  • Safety data from 9-month studies
  • How to identify quality CBD products (and avoid dangerous ones)
  • Drug interactions and when to consult your veterinarian
Veterinarian consulting with dog owner about CBD treatment options

Always Consult Your Veterinarian Before Starting CBD

⚠️ Important: This guide is for educational purposes only. CBD products are not FDA-approved drugs and are not intended to diagnose, treat, cure, or prevent any disease. Always consult your veterinarian before starting any supplement, especially if your dog has a medical condition or takes medications.

What is CBD?

Cannabis, Hemp, and Marijuana: Legal Definitions

CBD (cannabidiol) is one of over 90 naturally-occurring compounds called cannabinoids found in cannabis plants. But not all cannabis is the same—legally or chemically.

Hemp versus marijuana comparison - legal definitions and THC content

Hemp vs Marijuana: Critical Legal & Chemical Differences

✅ Hemp

  • Cannabis sativa with ≤0.3% THC
  • Federally legal (2018 Farm Bill)
  • Source of legal CBD products
  • Non-psychoactive

❌ Marijuana

  • Cannabis with >0.3% THC
  • Schedule I controlled substance
  • Psychoactive ("high")
  • Administer CAUTIOUSLY

💡 The Bottom Line: Legal CBD for dogs comes from hemp, not marijuana. The 0.3% THC threshold is critical—but as you'll learn, even trace THC can be dangerous for dogs.

CBD vs THC: Critical Differences

Factor CBD (Cannabidiol) THC (Tetrahydrocannabinol)
Psychoactive ❌ No ✅ Yes ("high")
Safe for Dogs ✅ Yes ✅ Yes, In Moderation
Tolerance ❌ No tolerance ✅ Rapid (3-8 days)
Long-Term Use ✅ Safe (9-month studies) ❌ Physical dependence
Legal Status ✅ Legal (from hemp) ❌ Schedule I

⚠️ Why This Matters for Dogs:

Research shows dogs have exceptionally high concentrations of cannabinoid receptors in the cerebellum—the part of the brain controlling motor function. This unique distribution makes dogs much more sensitive to THC than humans, causing:

  • Severe ataxia (loss of coordination)
  • Inability to stand or walk
  • Urinary incontinence
  • Hypothermia
  • Bradycardia (slow heart rate)

This is why VetsGrade products contain <0.3% THC as Federally Allowed. We eliminate the guesswork to protect your dog's sensitive brain chemistry.

Types of CBD Products

Full-Spectrum

All cannabinoids including THC (up to 0.3%)

⚠️ Moderate Risk: THC toxicosis in dogs

✅ Complete Entourage effect

CBD Isolate

99%+ pure CBD only

❌ Drawback: Misses "entourage effect"

✅ Broad-Spectrum

CBD + beneficial cannabinoids (CBG, CBC, CBDA)

✅ 0.0% THC (verified)

✅ Entourage effect without risk

🔬 The Entourage Effect: Research suggests multiple cannabis compounds work synergistically—CBD + terpenes + other cannabinoids may be more effective than CBD alone. Broad-spectrum provides these benefits without ANY THC risk.

How CBD Works in Dogs

The Endocannabinoid System (ECS)

Your dog has a built-in "cannabis system"—the endocannabinoid system (ECS). Discovered only a few decades ago, the ECS is a complex network of receptors and signaling molecules found throughout the body.

🧠 The ECS Regulates:

✅ Pain perception
✅ Inflammation response
✅ Mood and anxiety
✅ Sleep and wake cycles
✅ Appetite and metabolism
✅ Immune function
✅ Memory and learning
✅ Motor control

Key Components:

Endocannabinoid system diagram showing CB1 and CB2 receptors in dogs

The Endocannabinoid System in Dogs

CB1 Receptors

Location: Primarily brain and CNS

Control: Motor function, memory, pain, mood

⚠️ Dogs have HIGH concentrations in cerebellum (unique!)

CB2 Receptors

Location: Immune system, peripheral tissues

Control: Inflammation, immune response

✅ Increase during disease

✅ No psychoactive effects

Why Dogs Are Different: The Cerebellar Connection

🚨 Critical Research Finding:

Dogs have uniquely high concentrations of CB1 receptors in the cerebellum compared to humans and other species. This explains why:

  1. Dogs are MORE sensitive to THC's motor effects - Severe "static ataxia" (can't stand/walk) unique to canine species
  2. CBD may support motor function - Without psychoactive effects (CBD doesn't directly activate CB1R)
  3. Titrating THC is critical - Protects sensitive cerebellar receptors, reduces ataxia risk

How CBD Interacts with the ECS

Unlike THC (which directly activates receptors), CBD works indirectly:

1️⃣ Enhances Natural Endocannabinoids

Inhibits breakdown of anandamide (AEA), increases availability of your dog's own "bliss molecule"

2️⃣ Modulates Receptor Activity

Weak antagonist at CB1R (doesn't overstimulate), works through allosteric sites (no tolerance)

3️⃣ Interacts with Other Receptors

Serotonin (mood/anxiety), vanilloid (pain), GPR55 (bone health)

💡 The Result: CBD supports your dog's natural wellness systems without replacing them or causing dependence.

What Research Shows: Clinical Studies

The following clinical studies represent the most rigorous research on CBD for dogs. All are peer-reviewed and published in veterinary journals.

Clinical study results showing 94% response rate for CBD and dog arthritis

Key Clinical Study Results: CBD for Dogs

🦴 CBD for Arthritis & Joint Pain

Osteoarthritis affects approximately 20% of dogs over 1 year of age and up to 80% of dogs over 8 years. Traditional treatments (NSAIDs) can have significant side effects. Here's what research shows about CBD:

📊 Study #1: Cornell University (Gamble et al, 2018)

Study Design:

  • Placebo-controlled, randomized, crossover trial (gold standard)
  • 16 dogs with osteoarthritis
  • 1 month treatment + 2-week washout
  • Dogs could stay on NSAIDs, fish oil, glucosamine

Dosing: 2 mg/kg total cannabinoids (1 mg CBD + 1 mg CBDA), every 12 hours with food

✅ Results:
  • Significant reduction in pain scores (owner-reported via CBPI)
  • Significant increase in activity scores (Hudson scale)
  • Reduced pain indices at weeks 2 and 4 (veterinarian-assessed)

Safety: Elevated ALP in 9 of 16 dogs, but no interaction with NSAIDs (safe to combine)

✅ Conclusion: CBD significantly reduces pain and increases activity in arthritic dogs.

📊 Study #2: 90-Day Real-World Study (Kogan et al, 2020)

Study Design: 32 dogs completed 90-day trial, dose escalation protocol (0.25-0.75 mg/kg every 12 hours)

🎯 Results:
  • 30 of 32 dogs responded (94% success rate!)
  • Mean pain score: 3.2 → 1.0 (69% reduction)
  • Most dogs needed 1-2 mg/kg to achieve pain score 0-1
  • 94% of owners felt treatment positively impacted quality of life
🔥 Gabapentin Reduction (HUGE Finding):
  • 10 of 23 dogs completely discontinued gabapentin
  • 11 of 23 dogs reduced gabapentin dose by 62%
  • Average gabapentin: 1,846 mg/day → 710 mg/day

✅ Conclusion: 94% of dogs responded to CBD, with most achieving significant pain relief at 1-2 mg/kg twice daily. Many dogs reduced or eliminated gabapentin.

📋 Research Summary - Arthritis:

  • ✅ 94% response rate in clinical studies
  • ✅ 69% pain reduction (3.2 → 1.0 pain score)
  • ✅ Effective dose: 1-2 mg/kg twice daily
  • ✅ Results within 2-4 weeks
  • ✅ Safe with NSAIDs and other medications
  • ✅ 43% of dogs can stop gabapentin, 48% reduce dose
Senior dog with arthritis showing improvement with CBD treatment

Real Results: Improved Mobility & Quality of Life with CBD

Pet Parent Recommended for Arthritis

VetsGrade Relief+ CBD oil tincture for dogs
Relief+ Solventless Tincture

PhD & DVM Research-backed dosing useful in arthritis, inflammation, and joint discomfort

Shop Relief+ →

🧠 CBD for Seizures & Epilepsy

Epilepsy affects 0.5-5% of dogs. When seizures aren't controlled by traditional medications (refractory epilepsy), CBD may help as adjunct therapy.

📊 Study #1: McGrath et al (2019) - Placebo-Controlled

Study Design: Randomized, blinded, placebo-controlled (gold standard), 26 dogs enrolled, 17 completed

Dosing: 2.5 mg/kg every 12 hours (5 mg/kg/day total), CBD-rich hemp oil, 12-week trial

📈 Results:
  • ✅ CBD group: 4 → 2.7 seizures/month (33% reduction)
  • ❌ Placebo group: 2 → 2 seizures/month (no change)
  • ✅ 2 dogs in each group met 50% reduction threshold (22% responder rate)
  • ✅ Higher plasma CBD = greater seizure reduction

Safety: Significant ALP elevation, no changes in phenobarbital levels (safe combination)

📊 Study #2: Garcia et al, 2023 - BEST RESULTS

Study Design: 14 dogs, 24-week crossover, CBD+CBDA-rich hemp extract, 2 mg/kg twice daily

🎯 Results:
  • ✅ Seizure frequency: 8.0 → 5.0 over 12 weeks (37.5% reduction)
  • ✅ Seizure days: 5.8 → 4.1 (29% reduction)
  • ✅ 6 of 14 dogs (43%) had >50% reduction in seizures
  • ❌ 0 dogs on placebo had >50% reduction

✅ Conclusion: CBD+CBDA combination showed best results - 43% responder rate vs 22% in CBD-only study.

📋 Research Summary - Seizures:

  • ✅ 33-37.5% overall seizure reduction
  • ✅ 22-43% achieve >50% reduction (CBD+CBDA better)
  • ✅ Effective dose: 2-2.5 mg/kg twice daily
  • ✅ Safe with phenobarbital, potassium bromide, levetiracetam, zonisamide
  • ⚠️ NOT a cure - adjunct therapy only
  • ⚠️ NEVER replace seizure medications
  • ⚠️ ALWAYS use with veterinary supervision

🚨 CRITICAL WARNING:

CBD is an adjunct therapy for seizures, not a replacement for seizure medications. Never stop or reduce seizure medications without veterinary guidance. Always work with your veterinarian when using CBD for epilepsy.

😰 CBD for Anxiety & Stress

Approximately 70% of dogs experience some form of anxiety. Research shows CBD may help with situational anxiety, but results for chronic anxiety are mixed.

Calm, relaxed dog showing reduced anxiety with CBD

CBD Helps Dogs Achieve Calm, Relaxed State

📊 Study #1: Car Travel Anxiety (Flint et al, 2024)

Dosing: 4 mg/kg once daily for stress associated with car travel

✅ Results:
  • Reduced cortisol levels (stress hormone)
  • Reduced whining
  • Reduced lip licking
  • Improved qualitative behavioral ratings

✅ Conclusion: CBD effective for situational travel anxiety.

⚠️ Chronic Anxiety Studies:

4 studies found no difference between CBD and placebo for chronic behavioral issues

✅ Best results for situational anxiety (travel, vet visits, fireworks)
❌ May not work for severe aggression or chronic anxiety disorders

📋 Research Summary - Anxiety:

  • ✅ Situational anxiety: 4 mg/kg once, 30-60 min before event
  • ✅ Separation anxiety: 4 mg/kg daily or 2 mg/kg twice daily
  • ✅ Effective for: Car travel, vet visits, fireworks, thunderstorms
  • ⚠️ Chronic anxiety: Mixed results, may need comprehensive behavioral approach
  • ❌ Not effective for: Severe aggression, complex anxiety disorders

CBD Dosing for Dogs: Research-Based Guidelines

Based on clinical studies, here are evidence-based dosing recommendations:

📏 General Dosing Principles

1️⃣ Start Low, Go Slow

Begin at lower end of range, increase gradually if needed, allow 2 weeks at each dose before adjusting

2️⃣ Give Twice Daily

More consistent blood levels, better therapeutic effects, despite 7-9 hour half-life

3️⃣ ALWAYS Give With Food

3x better absorption with food, fat enhances bioavailability, consistent timing with meals

4️⃣ Be Patient

Allow 5-7 days to reach steady state, full effects may take 2-4 weeks, don't expect immediate results

📊 Dosing by Condition

Condition Dose Frequency Timeline
Arthritis/Joint Pain 1-2 mg/kg Twice daily with food 2-4 weeks
Seizures/Epilepsy 2-2.5 mg/kg Twice daily with food 4-12 weeks
Anxiety (Situational) 4 mg/kg Once, 30-60 min before event 1-2 hours
Anxiety (Chronic) 2 mg/kg Twice daily with food 2-4 weeks
Skin Allergies 2 mg/kg Twice daily with food 2-4 weeks
General Wellness 1-1.5 mg/kg Once or twice daily Ongoing
CBD dosing guide for dogs by weight and condition

Visual Dosing Guide by Dog Size & Condition

⚠️ Important Dosing Notes:

  • Higher Dose ≠ Better Results: Study showed 9 mg/kg had WORSE results than 2-4 mg/kg
  • Individual Variation: Some dogs respond to lower doses, others need upper end of range
  • Long-Term Use: No tolerance development (unlike THC), same dose remains effective

🧮 Calculate Your Dog's Exact Dose

Get personalized dosing based on your dog's weight and condition

Use Dosing Calculator →

Safety & Side Effects

🔬 Long-Term Safety Studies

9-Month Study

Dogs received 0, 5, or 10 mg/kg/day for 36 weeks

✅ Otherwise well-tolerated for 9 months

6-Month Study

40 healthy dogs, 4 mg/kg daily for 6 months

✅ All returned to normal 4 weeks after stopping

FDA Pre-Approval Studies

No adverse effects at doses up to 100 mg/kg/day

✅ Massive safety margin

CBD safety margin for dogs - 20-70x safer than recommended dose

Exceptional Safety Profile: 20-70x Safety Margin

CBD vs Other Treatments

CBD vs NSAIDs (Rimadyl, Previcox, Metacam)

Factor CBD NSAIDs
Efficacy 94% response rate (studies) Highly effective
Side Effects Minimal (elevated ALP, soft stool) GI ulcers, kidney/liver damage
Long-Term Safety Proven safe 9 months Requires monitoring, risks increase
Cost $40-60/month $30-80/month
Prescription No Yes
Can Combine? ✅ Yes (safe in studies) N/A
Comparison chart showing CBD versus traditional medications for dogs

CBD vs Traditional Medications: Side-by-Side Comparison

💡 Bottom Line: CBD can be used alone or combined with NSAIDs. Many dogs can reduce NSAID dose when using CBD, minimizing NSAID side effects.

CBD vs Gabapentin

🔥 Clinical Study Finding:

When dogs with arthritis started CBD:

  • 43% completely stopped gabapentin
  • 48% reduced gabapentin dose by 62%
  • Average gabapentin: 1,846 mg/day → 710 mg/day
  • Dogs were more alert and interactive (less sedation)

How to Give CBD to Your Dog

⚠️ Critical: ALWAYS Give With Food

Why This Matters: Research shows CBD absorption increases ~3x in dogs when given with food (up to 11x in cats!).

❌ Without Food:

Wasting 66% of CBD

✅ With Food:

Maximum Absorption

Best Practices: Give with regular meals, mix directly into food, give with high-fat treat (peanut butter, cheese), consistent timing

Owner giving CBD oil to dog with food - proper administration

Proper Administration: Always Give CBD With Food

📅 What to Expect: Timeline

Timeline showing when CBD starts working for dogs - from first dose to long-term results

CBD Effectiveness Timeline: What to Expect

First Dose

No immediate effects expected, CBD needs to build up in system

Days 1-7

Reaching steady-state blood levels, may notice subtle changes, be patient

Weeks 2-4

Full therapeutic effects develop, most noticeable improvements, optimal benefits

Long-Term

Sustained benefits, no tolerance development, consistent effects with same dose

Choosing Quality CBD: The Product Variability Crisis

🚨 The Shocking Truth About CBD Quality

Study of 183 Dogs Receiving CBD Products:

Researchers measured actual blood levels of CBD and THC in dogs receiving "CBD dietary supplements" from 40+ different products.

CBD Concentrations:

  • Range: Non-detectable to >1,000 ng/mL
  • Median: Only 13.7 ng/mL
  • Some products had NO detectable CBD!
  • Massive batch-to-batch variation

THC Concentrations:

  • Range: Non-detectable to 87.4 ng/mL
  • Median: 0.6 ng/mL
  • Some "CBD" products had significant THC!
  • Risk of toxicosis from mislabeled products

Researcher Conclusion: "This variability suggests that therapeutic drug monitoring of phytocannabinoids might be prudent in clinical patients."

Translation: Most CBD products are so unreliable that blood testing may be needed to verify your dog is actually getting CBD!

✅ How to Identify Quality CBD

Third-party lab testing for CBD quality and safety verification

Third-Party Lab Testing Ensures Quality & Safety

✅ MUST HAVE: Third-Party Testing

1️⃣ Independent Lab

NOT tested by company itself, accredited lab (ISO 17025), tests EVERY batch

2️⃣ Certificate of Analysis

Published and accessible, matches batch number, recent date, actual results

3️⃣ Comprehensive Testing

Cannabinoids, heavy metals, pesticides, microbials, residual solvents

4️⃣ THC Verification

Should show <0.3% Total THC or ND (non-detect)

🚩 Red Flag: If a company doesn't provide COAs or makes them hard to find, don't buy their products.

🏆 VetsGrade Quality Standards

How We Exceed Industry Standards

✅ Third-Party Testing

Independent lab (ISO 17025), EVERY batch tested, COA published online

✅ <0.3% THC Guarantee

Not just <0.3% - we verify EVERYTHING, protects sensitive canine receptors

✅ Broad-Spectrum

CBD + CBG + CBC + CBDA + terpenes, Solventless, MCT oil carrier

✅ Full Transparency

USDA-approved hemp, FDA-registered facilities, GMP certified, batch-traceable

Drug Interactions

Discuss CBD with your veterinarian to check for drug interactions

Always Discuss CBD With Your Veterinarian - Especially If Your Dog Takes Medications

CBD is metabolized by liver enzymes (CYP450 system) and can affect how other medications are processed.

How CBD Can Affect Other Medications

CBD Can:

  • Inhibit certain enzymes (CYP2C8, CYP2C9, CYP2C19)
  • Induce other enzymes (CYP1A2, CYP2B6)
  • Increase levels of some medications (potentially causing side effects)
  • Decrease levels of other medications (potentially reducing effectiveness)

⚠️ Medications of Concern

🚨 HIGH CONCERN: Seizure Medications

Documented Interaction:

Clobazam: CBD significantly increased levels (case report), may cause increased sedation, ataxia

Potential Interactions:

  • Phenobarbital (metabolized by CYP enzymes)
  • Zonisamide (metabolized by CYP enzymes)
  • Levetiracetam (less likely but monitor)
  • Potassium bromide (different metabolism, likely safe)

What to Do:

  • ✅ ALWAYS inform veterinarian before starting CBD
  • ✅ Baseline blood work (medication levels)
  • ✅ Recheck levels 2-4 weeks after starting CBD
  • ✅ Monitor for increased sedation or ataxia
  • ✅ Veterinarian may need to reduce medication doses (this is good - fewer side effects!)

⚠️ MODERATE CONCERN: NSAIDs

Medications: Carprofen (Rimadyl), Meloxicam (Metacam), Deracoxib (Deramaxx), Firocoxib (Previcox)

Research Shows: Some studies found safe combination, others showed increased liver enzyme elevation when combined (especially at higher CBD doses)

What to Do:

  • Use lower CBD doses when combining (2-3 mg/kg)
  • Monitor liver enzymes monthly for first 3 months
  • Watch for GI upset, loss of appetite
  • Consider trying CBD alone first (many dogs can reduce or eliminate NSAIDs)

✅ Positive Interactions: CBD May Allow Reduction Of

Gabapentin
  • 43% of dogs stopped completely
  • 48% reduced dose by 62%
  • Less sedation, better quality of life
NSAIDs
  • Some dogs can reduce dose
  • Fewer GI side effects
  • Lower kidney/liver risk

⚠️ Important: NEVER stop or reduce medications without veterinary guidance!

✅ Before Starting CBD - Checklist:

  • ☐ List ALL medications your dog takes (including supplements)
  • ☐ Inform your veterinarian about CBD use
  • ☐ Discuss potential interactions
  • ☐ Baseline blood work (if on medications)
  • ☐ Plan monitoring schedule
  • ☐ Know what to watch for (side effects, changes in effectiveness)

Frequently Asked Questions

❓ Is CBD legal for dogs?

Yes. CBD derived from hemp (≤0.3% THC) is federally legal under the 2018 Farm Bill and legal in all 50 states. VetsGrade products are hemp-derived with 0.0% THC, making them legal nationwide.

❓ Will CBD get my dog "high"?

No. CBD is non-psychoactive and does not cause a "high" or intoxication. The psychoactive compound in cannabis is THC. VetsGrade products contain 0.0% THC, eliminating any psychoactive effects.

❓ Does CBD really work for dogs?

Yes, according to clinical research:

  • 94% response rate for arthritis (pain reduction, increased activity)
  • 43% of dogs with epilepsy achieve >50% seizure reduction
  • Proven effective for situational anxiety (reduced stress, cortisol)
  • Reduces itching in dogs with skin allergies

Results vary by individual and condition. Not all dogs respond equally.

❓ How long does it take to work?

Timeline varies by condition:

  • Situational anxiety: 1-2 hours
  • Arthritis: 1-2 weeks for initial improvement, 4 weeks for maximum benefit
  • Seizures: 4-12 weeks to assess effectiveness
  • Chronic anxiety: 2-4 weeks
  • Skin allergies: 2-4 weeks

Allow 5-7 days to reach steady blood levels. Be patient!

❓ Can I give my dog too much CBD?

CBD has an exceptional safety margin. Studies show no adverse effects at doses up to 100 mg/kg/day - that's 35-70x higher than recommended doses (1.45-2.9 mg/kg).

However, higher doses can cause increased sedation, soft stool/diarrhea, and elevated liver enzymes. Stick to research-based doses for best results with minimal side effects.

❓ Will my dog develop tolerance to CBD?

No. Unlike THC (which causes tolerance within 3-8 days in dogs), CBD does not cause tolerance or physical dependence. Studies up to 9 months show consistent effects with no need for dose escalation.

❓ Is CBD safe for dogs?

Yes. Research shows:

  • Safe for up to 9 months of daily use (10 mg/kg)
  • Safe for 6 months at 4 mg/kg daily
  • No adverse effects at doses up to 100 mg/kg/day
  • Minimal side effects (elevated ALP, soft stool)
  • All side effects reversible

Recommended doses (1.45-2.9 mg/kg) are 20-70x lower than doses causing adverse effects.

❓ Can CBD interact with my dog's medications?

Yes, potentially. CBD can affect liver enzymes that metabolize many medications, potentially increasing or decreasing their levels.

Medications of concern:

  • Seizure medications (phenobarbital, zonisamide, clobazam)
  • NSAIDs (Rimadyl, Metacam)
  • Antifungals (ketoconazole, itraconazole)
  • Cardiac medications (amiodarone)
  • Immunosuppressants (tacrolimus)

Always inform your veterinarian before starting CBD, especially if your dog takes medications.

❓ How much CBD should I give my dog?

Depends on condition and weight:

  • Arthritis: 1-2 mg/kg twice daily
  • Seizures: 2-2.5 mg/kg twice daily
  • Situational anxiety: 4 mg/kg once, 30-60 min before event
  • Chronic anxiety: 2 mg/kg twice daily
  • Skin allergies: 2 mg/kg twice daily

Use our dosing calculator for your dog's exact dose →

❓ Do I have to give CBD with food?

YES - CRITICAL! Research shows CBD absorption increases ~3x when given with food in dogs (up to 11x in cats). Without food, you're wasting 66% of the CBD. Always give with meals for maximum effectiveness.

❓ Why is 0.0% THC better than <0.3%?

Dogs are uniquely sensitive to THC due to high concentrations of cannabinoid receptors in the cerebellum (motor control center).

Even small amounts of THC can cause:

  • Severe ataxia (loss of coordination)
  • Urinary incontinence
  • Hypothermia, bradycardia
  • Distress lasting 24-96 hours

0.0% THC eliminates ALL risk - no toxicosis, no tolerance, no psychoactive effects.

❓ Can CBD replace my dog's seizure medication?

NO - NEVER. CBD is an adjunct therapy for seizures, not a replacement. 43% of dogs achieve >50% seizure reduction when CBD is added to seizure medications. Never stop seizure medications without veterinary guidance.

❓ How long can my dog stay on CBD?

Indefinitely. Studies show CBD is safe for at least 9 months of daily use, and there's no evidence of harm from longer-term use. No tolerance development means effects remain consistent. Safe with proper monitoring (regular vet check-ups, blood work every 3-6 months).

❓ What's the difference between CBD oil and CBD treats?

CBD Oil (Tincture): More precise dosing by weight, faster absorption, easy to adjust dose, can mix with food. Recommended for therapeutic use.

CBD Treats: Pre-measured doses, convenient, dogs love them, but harder to dose precisely by weight. Better for general wellness than specific conditions.

❓ Can I use human CBD products for my dog?

Not recommended. Human CBD products may contain ingredients toxic to dogs (xylitol, chocolate, essential oils). They're also not formulated for canine dosing. Always use CBD products specifically formulated for pets with verified 0.0% THC.

Conclusion: Making an Informed Decision

CBD shows significant promise for supporting canine wellness, backed by clinical research showing:

  • ✅ 94% response rate for arthritis with meaningful pain reduction
  • ✅ 43% of epileptic dogs achieve >50% seizure reduction
  • ✅ Proven effective for situational anxiety and stress
  • ✅ Reduces itching in dogs with skin allergies
  • ✅ Exceptional safety profile with 20-70x safety margin
  • ✅ Well-tolerated for long-term daily use (9-month studies)
  • ✅ No tolerance development - consistent effects over time

But CBD is not a miracle cure. It:

  • ❌ Doesn't work for every dog or every condition
  • ❌ Cannot replace veterinary care or diagnosis
  • ❌ Should not replace proven medications (especially for seizures)
  • ❌ Requires patience (2-4 weeks for full effects)
  • ❌ Needs proper dosing and quality products to be effective

Your Next Steps

1️⃣ Consult Your Veterinarian

  • Discuss whether CBD is appropriate
  • Review medications for interactions
  • Plan monitoring schedule
  • Set realistic expectations

2️⃣ Choose Quality Products

  • Third-party tested (every batch)
  • 0.0% THC verified
  • Accurate labeling
  • Transparent company

3️⃣ Start Smart

  • Use research-based dosing
  • Give with food (critical!)
  • Twice daily for therapeutic use
  • Be patient (allow 2-4 weeks)

4️⃣ Monitor & Adjust

  • Baseline blood work
  • Watch for improvements
  • Note any side effects
  • Regular vet check-ups

VetsGrade: Research-Backed CBD for Dogs

Formulated based on AVMA research. Tested for quality and safety. Trusted by veterinarians.

✅ AVMA-Informed

Dosing aligned with clinical studies, <0.3% THC

✅ Quality Verified

Third-party tested every batch, COA published

✅ Transparent

No illegal claims, educational approach

✅ Exceptional Value

Research-based dosing, 20-70x safety margin

References

  1. Brutlag A, Hommerding H. Toxicology of marijuana synthetic cannabinoids, and cannabidiol in dogs and cats. Vet Clin North Am Small Anim Pract. 2018;48:1087-1102.
  2. Agriculture Improvement Act of 2018 (2018 Farm Bill). Accessed February 1, 2024. https://www.congress.gov/bill/115th-congress/house-bill/2/text
  3. Controlled Substances Act of 1971, 21 U.S. Code Section 201 (2018).
  4. Agricultural Marketing Services, USDA. Establishment of a domestic hemp production program. Fed Regist. 2019:84:58522.
  5. Pacula RL, Smart R. Medical marijuana and marijuana legalization. Annu Rev Clin Psychol. 2017;13:397-419.
  6. Zlas J, Stark H, Sellgman, et al. Early medical use of cannabis. Nature. 1993;363(6426):215.
  7. Hand A, et al. History of medical cannabis. Cannabis: Med Aspects. 2016;9:387-394.
  8. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother. 2006;40(2):251-260.
  9. Kreitzer FR, Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther. 2009;122(2):83-96.
  10. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180-188.
  11. Drug Enforcement Agency. The early years. Cited July 25, 2020. https://www.dea.gov/sites/default/files/2018-05/Early%20Years%20p%2012-29.pdf
  12. Schaffer Library of Drug Policy. The Marihuana Tax Act of 1937. Cited July 25, 2020. https://www.druglibrary.org/schaffer/hemp/taxact/mjtaxact.htm
  13. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(suppl 1):S163-171.
  14. Legislative Counsel's Digest, California AB 223. Accessed February 1, 2024. https://legiscan.com/CA/text/AB223/id/2838619
  15. Abrams DI. The therapeutic effects of Cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018;49:7-11.
  16. FDA. Inapplicability of the dietary supplement health and education act to animal products. Cited July 25, 2020. https://www.federalregister.gov/documents/1996/04/22/96-9780/inapplicability-of-the-dietary-supplement-health-and-education-act-to-animal-products
  17. McPartland JM. Cannabis systematics at the levels of family, genus, and species. Cannabis Cannabinoid Res. 2018;3(1):203-212.
  18. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19.
  19. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30(10):515-527.
  20. Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth. 2008;101(1):59-68.
  21. Thomas BF, ElSohly MA. Chapter 2 – Biosynthesis and pharmacology of phytocannabinoids and related chemical constituents. In: Thomas BF, ElSohly MA, eds. The Analytical Chemistry of Cannabis. Elsevier;2016:27-41.
  22. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.
  23. Deiana S. Potential medical uses of cannabigerol: a brief overview. In: Preedy VR, ed. Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment. Elsevier;2017:958-967.
  24. Thomas BF, ElSohly MA. Chapter 1 – The botany of Cannabis sativa L. In: Thomas BF, ElSohly MA, eds. The Analytical Chemistry of Cannabis. Elsevier;2016:1-26.
  25. FDA. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Cited July 25, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
  26. Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133-150.
  27. De Luca MA, Fattore L. Therapeutic use of synthetic cannabinoids: still an open issue? Clin Ther. 2018;40(9):1457-1466.
  28. Ammann J, McLaren JM, Gerostamoulos D, Beyer J. Detection and quantification of new designer drugs in human blood: Part 1 – Synthetic cannabinoids. J Anal Toxicol. 2012;36(6):372-380.
  29. Synthetic Drug Abuse Prevention Act 2012 S.3190 12th Congress.
  30. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernández-Ruiz J. The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther. 2002;95(2):137-152.
  31. Howlett AC, Abood ME. CB1 and CB2 receptor pharmacology. Adv Pharmacol. 2017;80:169-206.
  32. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516-525.
  33. Chanda D, Neumann D, Glatz JFC. The endocannabinoid system: Overview of an emerging multifaceted therapeutic target. Prostaglandins Leukot Essent Fatty Acids. 2019;140:51-56.
  34. Hebert-Chatelain E, Marsicano G, Desprez T. Cannabinoids and mitochondria. In: Melis M, ed. Endocannabinoids and Lipid Mediators in Brain Functions. Springer;2017:211-235.
  35. Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016;96(4):1593-1659.
  36. Geppetti P, Veldhuis NA, Lieu TM, Bunnett NW. G protein-coupled receptors: dynamic machines for signaling pain and itch. Neuron. 2015;88(4):635-649.
  37. Panlilio LV, Goldberg SR, Justinova Z. Cannabinoid abuse and addiction: Clinical and preclinical findings. Clin Pharmacol Ther. 2015;97(6):616-627.
  38. Slivicki RA, Xu Z, Kulkarni P, et al. Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence. Biol Psychiatry. 2018;84(10):722-733.
  39. Bushlin I, Gupta A, Stockton SD Jr, Miller LK, Devi LA. Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One. 2012;7(12):e49789.
  40. Morales P, Reggio PH. An update on non-CB(1), non-CB(2) cannabinoid related G-protein-coupled receptors. Cannabis Cannabinoid Res. 2017;2(1):265-273.
  41. Fisar Z. Phytocannabinoids and endocannabinoids. Curr Drug Abuse Rev. 2009;2(1):51-75.
  42. Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology. 2018;43(1):155-172.
  43. Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3216-28.
  44. Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocannabinoid system and energy metabolism. J Neuroendocrinol. 2008;20(6):850-857.
  45. Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 2017;70(pt B):319-327.
  46. Donvito G, Nass SR, Wilkerson JL, et al. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 2018;43(1):52-79.
  47. Witkamp R. Fatty acids, endocannabinoids and inflammation. Eur J Pharmacol. 2016;785:96-107.
  48. Moreno E, Cavic M, Krivokuca A, Casadó V, Canela E. The endocannabinoid system as a target in cancer diseases: Are we there yet? Front Pharmacol. 2019;10:339.
  49. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3).
  50. Sierra S, Luquin N, Navarro-Otano J. The endocannabinoid system in cardiovascular function: novel insights and clinical implications. Clin Auton Res. 2018;28(1):35-52.
  51. DiPatrizio NV. Endocannabinoids in the gut. Cannabis Cannabinoid Res. 2016;1(1):67-77.
  52. Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain–gut axis. Gastroenterology. 2016;151(2):252-266.
  53. Acharya N, Penukonda S, Shcheglova T, Hagymasi AT, Basu S, Srivastava PK. Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proc Natl Acad Sci U S A. 2017;114(19):5005.
  54. Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol. 2018;157:122-133.
  55. Hedlund P. Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol Urodyn. 2014;33(1):46-53.
  56. Watkins BA, Hutchins H, Li Y, Seifert MF. The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health. J Nutr Biochem. 2010;21(12):1141-1152.
  57. Walker OLS, Holloway AC, Raha S. The role of the endocannabinoid system in female reproductive tissues. J Ovarian Res. 2019;12(1):3.
  58. Nielsen JE, Rolland AD, Rajpert-De Meyts E. Characterisation and localisation of the endocannabinoid system components in the adult human testis. Sci Rep. 2019;9(1):12866. Erratum in: Sci Rep. 2020;10(1):1267.
  59. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613-623.
  60. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(S1):11s-19s.
  61. Shinjyo N, Di Marzo V. The effect of cannabichromene on adult neural stem/progenitor cells. Neurochem Int. 2013;63(5):432-437.
  62. Izzo AA, Capasso R, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012;166(4):1444-1460.
  63. Marinol [package insert]. AbbVie Inc, North Chicago;2017.
  64. Epidiolex [package insert]. Greenwich Sciences, Carlsbad, CA;2018.
  65. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-1804.
  66. Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053-1067. Erratum in: CNS Drugs. 2019;33(4):397.
  67. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metabolism Reviews. 2013;46(1):86-95.
  68. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246-1251.
  69. Martin BR, Dewey WL, Harris LS, Beckner JS. 3H-delta9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs. J Pharmacol Exp Ther. 1976;196(1):128-144.
  70. Dall'Aglio C, Mercati F, Pascucci L, Boiti C, Pedini V, Ceccarelli P. Immunohistochemical localization of CB1 receptor in canine salivary glands. Vet Res Commun. 2010;34(suppl 1):S9-12.
  71. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932-1936.
  72. Freundt-Revilla J, Kegler K, Baumgärtner W, Tipold A. Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS One. 2017;12(7):e0181064.
  73. Campora L, Miragliotta V, Ricci E, Cristino L. Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. Am J Vet Res. 2012;73(7):988-995.
  74. Ndong C, O'Donnell D, Ahmad S, Groblewski T. Cloning and pharmacological characterization of the dog cannabinoid CB(2) receptor. Eur J Pharmacol. 2011;669(1-3):24-31.
  75. Freundt-Revilla J, Heinrich F, Zoerner A, et al. The endocannabinoid system in canine steroid-responsive meningitis-arteritis and intraspinal spirocercosis. PLoS One. 2018;13(2):e0187197.
  76. Dewey WL, Jenkins J, O'Rourke T, et al. The effects of chronic administration of trans-9-tetrahydrocannabinol on behavior and the cardiovascular system of dogs. Arch Int Pharmacodyn Ther. 1972;198(1):118-131.
  77. KaymakÇalan Ş, Türker RK, Türker MN. Analgesic effect of Δ9-tetrahydrocannabinol in the dog. Psychopharmacologia. 1974;35(2):123-128.
  78. Garrett ER. Pharmacokinetics and disposition of Δ9-tetrahydrocannabinol and its metabolites. In: Nahas GG, Paton WDM, eds. Marihuana Biological Effects. Pergamon;1979:105-121.
  79. Garrett ER, Hunt CA. Pharmacokinetics of Δ9-tetrahydrocannabinol in dogs. J Pharm Sci. 1977;66(3):395-407.
  80. Samara E, Bialer M, Harvey DH. Identification of urinary metabolites of cannabidiol in the dog. Drug Metab Dispos. 1990;18(5):571-579.
  81. Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. Animals (Basel). 2019;9(10):832.
  82. Gamble LJ, Boesch JM, Frye CW, et al. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front Vet Sci. 2018;5:165.
  83. Bartner LR, McGrath S, Rao S, Hyatt LK, Wittenburg LA. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Can J Vet Res. 2018;82(3):178-183.
  84. McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. 2019;254(11):1301-1308.
  85. George JA, Driggers BJ, Cruz-Espindola C, Hargis CL, Harmon RR, Boothe DM. Variability in plasma cannabidiol concentrations in dogs receiving CBD-containing products. Presented at the American College of Veterinary Internal Medicine Forum, 2020.
  86. Teitler JB. Evaluation of a human on-site urine multidrug test for emergency use with dogs. J Am An Hosp Assoc. 2009;45(2):59-66.
  87. Vaughn D, Kulpa J, Paulionis L. Preliminary Investigation of the safety of escalating cannabinoid doses in healthy dogs. Front Vet Sci. 2020;7:51.
  88. McGrath S, Bartner LR, Rao S, Kogan LR, Hellyer PW. A report of adverse effects associated with the administration of cannabidiol in healthy dogs. J Amer Hol Vet Med Assoc. 2018;52:34-38.
  89. Boothe DM, Warner CG, Gillette R, Strunck R, Hargis C, Cruz-Espindola C. The disposition of cannabidiol in dogs after a single dose oral administration. Auburn University Phi Zeta Honors Society Poster.
  90. Wakshlag JJ, Schwark WS, Deabold KA, et al. Pharmacokinetics of cannabidiol, cannabidiolic acid, Δ9-tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. Front Vet Sci. 2020;7:505.
  91. Hannon MB, Deabold KA, Talsma BN, et al. Serum cannabidiol, tetrahydrocannabinol (THC) and their native acid derivatives after transdermal application of a low THC Cannabis sativa extract in beagles. J Vet Pharm Ther. 2020;43(5):508-511.
  92. Tittle DJ, Wakshlag JJ, Schwark WS, Lyubimov A, Zakharov A, Gomez B. Twenty-four hour and one-week steady state pharmacokinetics of cannabinoids in two formulations of cannabidiol and cannabidiolic acid rich hemp in dogs. Med Res Arch. 2022;10(7).
  93. Vaughn DM, Paulionis LJ, Kulpa JE. Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs. Am J Vet Res. 2021;82(5):405-416.
  94. Chicoine A, Illing K, Vuong S, Pinto KR, Alcorn J, Cosford K. Pharmacokinetic and safety evaluation of various oral doses of a novel 1:20 THC:CBD cannabis herbal extract in dogs. Front Vet Sci. 2020 Sep 29:7:583404.
  95. Corsato Alvarenga I, Gustafson D, Banks K, Wilson K, McGrath S. Cannabidiol plasma determination and pharmacokinetics conducted at beginning, middle and end of long-term supplementation of a broad-spectrum hemp oil to healthy adult dogs. Front Vet Sci. 2023;10:1279926.
  96. Corsato Alvarenga I, Wilson KM, McGrath S. Tolerability of long-term cannabidiol supplementation to healthy adult dogs. J Vet Intern Med. 2024;38(1):326-335.
  97. Mills T, Myers S, Hughes D, Wakshlag J. Tolerability of 2 and 4 mg/kg dosing every 12 hour of a cannabidiol- and cannabidiolic acid-rich hemp extract on mixed-breed dogs utilized for teaching in a closed colony. Animals (Basel). 2024 Jun 24;14(13):1863.
  98. Limsuwan S, Phonsatta N, Panya A, Asasutjarit R, Tansakul N. Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs. Front Vet Sci. 2024 Apr 25;11:1389810.
  99. Polidoro D, Temmerman R, Devreese M, et al. Pharmacokinetics of cannabidiol following intranasal, intrarectal, and oral administration in healthy dogs. Front Vet Sci. 2022;9:899940.
  100. Della Rocca G, Paoletti F, Conti MB, et al. Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs. Front Vet Sci. 2023;9:1104152.
  101. Jukier T, Cruz-Espindola C, Martin D, Boothe DM. Disposition of a single oral dose of a cannabidiol medication in healthy cats. Front Vet Sci. 2023;10:1181517.
  102. Lyons C, McEwan K, Munn-Patterson M, Vuong S, Alcorn J, Chicoine A. Pharmacokinetic of two oral doses of a 1:20 THC:CBD cannabis herbal extract in cats. Front Vet Sci. 2024 Feb 23;11:1352495.
  103. Rozental AJ, Gustafson DL, Kusick BR, Bartner LR, Castro SC, McGrath S. Pharmacokinetics of escalating single-dose administration of cannabidiol to cats. J Vet Pharmacol Ther. 2023;46(1):25-33.
  104. Kulpa JE, Paulionis LJ, Eglit GM, Vaughn DM. Safety and tolerability of escalating cannabinoid doses in healthy cats. J Feline Med Surg. 2021 Dec;23(12):1162-1175.
  105. Wang T, Zakharov A, Gomez B, et al. Serum cannabinoid 24 h and 1 week steady state pharmacokinetic assessment in cats using a CBD/CBDA rich hemp paste. Front Vet Sci. 2022;9:895368.
  106. Coltherd JC, Bednall R, Bakke AM, et al. Healthy cats tolerate long-term daily feeding of cannabidiol. Front Vet Sci. 2024 Jan 24;10:1324622.
  107. Kogan L, Hellyer PW, Robinson N. Consumers' perceptions of hemp products for animals. J Amer Hol Vet Med Assoc. 2016;42:40-48.
  108. Kogan L, Hellyer PW, Downing RD. The use of cannabidiol rich hemp oil extract to treat canine osteoarthritis related pain: A pilot study. J Amer Hol Vet Med Assoc. 2020;58:35-45.
  109. Verrico CD, Wesson S, Konduri V, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. 2020;161(90):2191-2202.
  110. Brioschi FA, Di Cesare F, Gioeni D, et al. Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals (Basel). 2020;10(9):1505.
  111. Klatzkow S, Davis G, Shmalberg J, et al. Evaluation of the efficacy of a cannabidiol and cannabidiolic acid rich hemp extract for pain in dogs following a tibial plateau leveling osteotomy. Front Vet Sci. 2023;9:1036056.
  112. Mejia S, Duerr FM, Griffenhagen G, McGrath S. Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs. J Am Anim Hosp Assoc. 2021;57(2):81-90.
  113. Talsma B, Elam LH, McGrath S, Zhou T, Webb CB, Duerr FM. Evaluation of the effect of cannabidiol administration with and without nonsteroidal anti-inflammatory drugs in dogs with mobility disorders: a prospective, double-blind, crossover, placebo-controlled study. Front Vet Sci. 2024 Sep 25;11:1449343.
  114. Casas-Alvarado A, Martínez-Burnes J, Hernández-Ávalos I, et al. Assessment of the nociceptive response to the use of cannabidiol alone and in combination with meloxicam through infrared pupillometry in female dogs undergoing elective ovariohysterectomy. Front Vet Sci. 2024 Jul 4;11:1380022.
  115. Hasckel Gewehr JL, Enzele ML, et al. Full spectrum cannabidiol-rich extract reduced propofol dosage required for anesthetic induction in dogs-a pilot study. Front Vet Sci. 2024 Apr 5:11:1352314.
  116. Rozental AJ, Weisbeck BG, Corsato Alvarenga I, et al. The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study. J Vet Intern Med. 2023;37(6):2291-2300.
  117. Garcia GA, Kube S, Carrera-Justiz S, Tittle D, Wakshlag JJ. Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs. Front Vet Sci. 2022;9:939966.
  118. Corsetti S, Borruso S, Malandrucco L, et al. Cannabis sativa L. may reduce aggressive behaviour towards humans in shelter dogs. Sci Rep. 2021;11(1):2773. Erratum in: Sci Rep. 2021;11(1):24029.
  119. Morris EM, Kitts-Morgan SE, Spangler DM, et al. Feeding cannabidiol (CBD)-containing treats did not affect canine daily voluntary activity. Front Vet Sci. 2021;8:645667.
  120. Marliani G, Vaccari L, Cavallini D, Montesano CS, Buonaiuto G, Accorsi PA. Assessing the effectiveness of cannabidiol additive supplementation on canine behavior and cortisol levels. Heliyon. 2024 May 15;10(10):e31345.
  121. Morris EM, Kitts-Morgan SE, Spangler DM, McLeod KR, Costa JHC, Harmon DL. The impact of feeding cannabidiol (CBD) containing treats on canine response to a noise-induced fear response test. Front Vet Sci. 2020;7:569565.
  122. Flint HE, Hunt ABG, Logan DW, King T. Daily dosing of cannabidiol (CBD) demonstrates a positive effect on measures of stress in dogs during repeated exposure to car travel. J Anim Sci. 2024 Jan 3;102:skad414.
  123. Masataka N. Possible effects of cannabidiol (CBD) administration on the vocal activity of healthy domestic dogs upon their temporary separation from caregivers. Heliyon. 2024 Jan 30;10(3):e25548.
  124. Loewinger M, Wakshlag JJ, Bowden D, Peters-Kennedy J, Rosenberg A. The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis. Vet Dermatol. 2022;33(4):329-e77.
  125. Mogi C, Yoshida M, Kawano K, Fukuyama T, Arai T. Effects of cannabidiol without delta-9-tetrahydrocannabinol on canine atopic dermatitis: A retrospective assessment of 8 cases. Can Vet J. 2022;63(4):423-426.
  126. Coelho JC, Duarte N, Bento da Silva A, Bronze MdR, Mestrinho LA. Placebo-controlled trial of daily oral cannabidiol as adjunctive treatment for cats with chronic gingivostomatitis. Animals. 2023;13(17):2716.
  127. Zanelli GR, Vieira GBM, Souza RVM, Aguiar AJdeA, Cassu RN. Perioperative analgesic and sedative effects of cannabidiol in cats undergoing ovariohysterectomy. Animals. 2024;14(16):2286.
  128. Weller JE, Flint HE, Hunt ABG, Ellerby Z, King T. Investigating the effect a single dose of cannabidiol has on measures of stress in cats when being transported in a carrier and meeting a novel person in an unfamiliar environment. Front Vet Sci. 2024 Nov 4;11:1476296.
  129. FDA Center for Drug Evaluation and Research. Application No. 210365Orig1s000. Non-clinical review(s). Accessed January 31, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000PharmR.pdf
  130. FDA Center for Drug Evaluation and Research. Application No. 210365Orig1s000. Summary review. Accessed January 31, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000SumR.pdf
  131. Bradley S, Young S, Bakke AM, et al. Long-term daily feeding of cannabidiol is well-tolerated by healthy dogs. Front Vet Sci. 2022;9:977457.
  132. Corsato Alvarenga I, Wilson KM, McGrath S. Tolerability of long-term cannabidiol supplementation to healthy adult dogs. J Vet Intern Med. 2024 Jan-Feb;38(1):326-335.
  133. Jost HE, Spitznagel K, Alvarenga IC, Peraza J, Banks K, McGrath S, de Linde Henriksen M. Long-term effect of oral cannabidiol administration to healthy adult dogs on tear production, intraocular pressure, and tear concentrations. Vet Ophthalmol. 2024 Jul;27(4):357-366.
  134. Ellis KL, Contino EK. Treatment using cannabidiol in a horse with mechanical allodynia. Eq Vet Ed. 2019;1-4.
  135. Jones K, Draeger A, Porr S. Murray State University School of Agriculture. Evaluation of CBD supplementation in the horse. Abstract poster presentation. Accessed January 31, 2024. https://digitalcommons.murraystate.edu/cgi/viewcontent.cgi?article=3402&context=postersatthecapitol
  136. Thomson ACS, McCarrel TM, Zakharov A, et al. Pharmacokinetics and tolerability of single-dose enteral cannabidiol and cannabidiolic acid rich hemp in horses (Equus caballus). Front Vet Sci. 2024 Apr 12;11:1356463.
  137. Eichler F, Ehrle A, Jensen KC, et al. Behavioral observations, heart rate and heart rate variability in horses following oral administration of a cannabidiol containing paste in three escalating doses (part 1& 2/2). Front Vet Sci. 2023 Dec 11;10:1305868.
  138. Nie B, Henion J, Wakshlag J. Analysis of veterinary hemp-based oils for product integrity by LC/MS. Cannabis Sci and Tech. 2019;2(3):36-45.
  139. Consumer Lab. CBD and Hemp Extracts Supplements Review, 2019. Accessed July 16, 2019. https://www.consumerlab.com/reviews/cbd-oil-hemp-review/cbd-oil/12
  140. Vandrey R, Raber JC, Raber ME, et al. Cannabinoid dose and label accuracy in edible medical cannabis products. J Am Med Assoc. 2015;313(24):2491–2493.
  141. Smith B. Quantitation of cannabinoids in dried ground hemp by mid-infrared spectroscopy. Cannabis Sci Tech. 2019;2(6):5-6.
  142. Steimling J, Kahler T. Liquid chromatography's complementary role to gas chromatograph in cannabis testing. LCGC Suppl. 2018;36(6):36-40.
  143. Rigdon A, Sweeney C, King C, Cassidy B, Kowalski J, Dorman F. Method validation for cannabis analytical labs: approaches to addressing unique industry challenges. Cannabis Science Conference, 2017:Portland, OR.
  144. Hazekamp A, Fischedick JT. Cannabis—from cultivar to chemovar. Drug Test Anal. 2011;4:660-667.
  145. Jones BR, Schultz GA, Eckstein JA, Ackermann BL. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis. 2012;4(19):2343-2356.
  146. Pertwee RG. Handbook of Cannabis. Oxford Press, 2014:1-781.
  147. Wedman-St. Louis B. Cannabis: A Clinician's Guide. CRC Press, 2018;288.
  148. Roberts C. Cali's dirty cannabis crisis: popular edibles claimed to be tainted with pesticides. Accessed February 1, 2024. https://hightimes.com/news/calis-dirty-cannabis-crisis-popular-edibles-claimed-to-be-tainted-with-pesticides
  149. Schaneman B. Cost of new mandatory marijuana pesticide testing tough to absorb for Colorado's growers. Accessed February 1, 2024. https://mjbizdaily.com/cost-of-new-mandatory-marijuana-pesticide-testing-tough-to-absorb-for-colorados-growers/
  150. Environmental Protection Agency. Pesticide products registered for use on hemp. Accessed February 1, 2024. https://19january2021snapshot.epa.gov/pesticide-registration/pesticide-products-registered-use-hemp_.html
  151. FDA. Summitt Labs issues voluntary nationwide recall of Kore organic watermelon CBD oil due to high lead results. Accessed February 1, 2024. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/summitt-labs-issues-voluntary-nationwide-recall-kore-organic-watermelon-cbd-oil-due-high-lead
  152. Schroyer S. California issues recalls for 29 marijuana firms caught in Sequoia Labs fallout. Accessed February 1, 2024. https://mjbizdaily.com/california-issues-recalls-29-marijuana-companies-sequoia-labs-fallout
  153. Mcdonough E. Colorado edibles recalled due to pesticides. Accessed February 1, 2024. https://hightimes.com/edibles/colorado-edibles-recalled-due-to-pesticides
  154. Regulations, C.C.O., Bureau Of Cannabis Control Proposed Text Of Regulations, in 16, D.B.O.C. Control, Editor. 2017: California. p. 1-136.
  155. New York State Environmental Laboratory Approval Program. Requirements for Laboratory Certification/Certification Manual. Determination of the Plant Growth Regulator Indole-3-butyric Acid and Pesticides in Medical Marijuana using LC-MS/MS. Department of Health, Wadsworth Center, 2018.
  156. Leppanen SD, Ebling H, Macherone A. Optimized cannabis microbial testing: combined use of extraction methods and pathogen detection tests using quantitative polymerase chain reaction. Cannabis Sci Tech. 2019;2(4).
  157. Gauvin DV, Zimmerman ZJ, Yoder J, Tapp R. Marijuana toxicity: heavy metal exposure through state-sponsored access to "la fee verte". Pharmaceut Reg Affairs: Open Access. 2018;7(1).
  158. Wang T. Liquid chromatography–inductively coupled plasma mass spectrometry (LC–ICP–MS). J Liq Chromatogr Rel Tech. 2007;30(5-7):807-831.
  159. Filipiak-Szok A, Kurzawa M, Szlyk E. Determination of toxic metals by ICP-MS in Asiatic and European medicinal plants and dietary supplements. J Trace Elem Med Biol. 2015;30:54-58.
  160. United States Department of Agriculture. Sampling Guidelines for Hemp. Accessed February 1, 2025. https://www.ams.usda.gov/sites/default/files/media/SamplingGuidelinesforHemp.pdf
  161. ISO. ISO/IEC 17025 – General requirements for the competence of testing and calibration laboratories. ISO, 2017.
  162. Meola SD, Tearney CC, Sharlee AH, Hackett TB, Mazzaferro EM. Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010). J Vet Emerg Crit Care. 2012;22(6):690-696.
  163. Donaldson CW. Marijuana exposure in animals. Vet Med. 2002;6:437-439.
  164. Janczyk P, Donaldson CW, Gwaltney S. Two hundred and thirteen cases of marijuana toxicosis in dogs. Vet Human Toxicol. 2004;46(1):19-21.
  165. Fitzgerald KT, Bronstein AC, Newuist KL. Marijuana poisoning. Top Companion Anim Med. 2013;28:8-12.
  166. Agnieszka J, Zawadzki M, Szpot P, Niedzwiedz A. Marijuana intoxication in a cat. Acta Vet Scand. 2018;60(44).
  167. Williams K, Wells RJ, McLean MK. Suspected synthetic cannabinoid toxicosis in a dog. J Vet Emerg Crit Care. 2015;25:739-744.
  168. Gugelmann H, Gerona R, Li C, et al. "Crazy Monkey" poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol. 2014;52:93-98.
  169. Centers for Disease Control and Prevention. Update—outbreak of life-threatening coagulopathy associated with synthetic cannabinoids use. Accessed February 1, 2024. https://emergency.cdc.gov/han/han00416.asp
  170. Pet Poison Helpline case database. Bloomington, MN: Pet Poison Helpline & SafetyCall International, PLLC; established 2004.
  171. Gidal BE. Drug interactions with cannabidiol (CBD): cause for concern? Accessed February 1, 2024. https://www.fda.gov/media/128362/download
  172. Effect of EPIDIOLEX on other drugs: highlights of prescribing information. Accessed February 1, 2024. https://www.epidiolex.com/sites/default/files/pdfs/0820/EPX-03645-0820_EPIDIOLEX_(cannabidiol)_USPI.pdf
  173. Fernandez AL, Lee JA, Rahilly LJ, et al. The use of intravenous lipid emulsion as an antidote in veterinary toxicology. J Vet Emerg Crit Care. 2011;21(4):309-320.
  174. FDA. Establishment of a domestic hemp production program. Fed Regist. 2021;86:5596. Accessed February 1, 2024. https://www.federalregister.gov/documents/2021/01/19/2021-00967/establishment-of-a-domestic-hemp-production-program
  175. Federal Food, Drug, and Cosmetic Act of 1938. 21 U.S. Code Section 321-399i.
  176. FDA. Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research; Draft Guidance for Industry; Availability. Accessed February 1, 2024. https://www.federalregister.gov/documents/2020/07/22/2020-15907/cannabis-and-cannabis-derived-compounds-quality-considerations-for-clinical-research-draft-guidance
  177. Federal Food, Drug, and Cosmetic Act of 1938. 21 U.S. Code Section 321(g).
  178. Federal Food, Drug, and Cosmetic Act. 21 U.S. Code Section 321(v).
  179. FDA. Regulations regarding Intended Uses. Accessed April 3, 2024 at https://www.federalregister.gov/documents/2021/08/02/2021-15980/regulations-regarding-intended-uses.
  180. Federal Food, Drug, and Cosmetic Act of 1938. 21 U.S. Code Section 801.4
  181. FDA. From an idea to the marketplace: the journey of an animal drug through the approval process. Accessed February 1, 2024. https://www.fda.gov/animal-veterinary/animal-health-literacy/idea-marketplace-journey-animal-drug-through-approval-process
  182. Federal Food, Drug, and Cosmetic Act. 21 U.S. Code Section 514.
  183. FDA. FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns. Cited July 15, 2020. https://www.fda.gov/news-events/press-announcements/fda-warns-15-companies-illegally-selling-various-products-containing-cannabidiol-agency-details
  184. FDA. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Accessed February 1, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
  185. FDA. Biota Biosciences issues voluntary nationwide recall of cannabidiol (CBD) complex, curcumin complex, and cannabidiol + curcumin injectables because they were marketed without FDA approval. Cited July 25, 2020. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/biota-biosciences-issues-voluntary-nationwide-recall-cannabidiol-cbd-complex-curcumin-complex-and
  186. FDA. FDA concludes that existing regulatory frameworks for foods and supplements are not appropriate for cannabidiol, will work with Congress on a new way forward. Accessed February 1, 2024. https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol
  187. FDA. FDA, FTC warn six companies for illegally selling copycat food products containing delta-8 THC. Accessed February 1, 2024. https://www.fda.gov/news-events/press-announcements/fda-ftc-warn-six-companies-illegally-selling-copycat-food-products-containing-delta-8-thc
  188. Federal Food, Drug. and Cosmetic Act. 21 U.S. Code Section 321(f).
  189. Federal Food, Drug, and Cosmetic Act. 21 U.S. Code Section 321(w).
  190. Federal Food, Drug, and Cosmetic Act. 21 U.S. Code Section 355.
  191. FDA. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). Accessed February 1, 2024. https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
  192. FDA. FDA responds to three GRAS notices for hemp seed-derived ingredients for use in human food. Cited July 25, 2020. https://www.fda.gov/food/cfsan-constituent-updates/fda-responds-three-gras-notices-hemp-seed-derived-ingredients-use-human-food
  193. Federal Food, Drug, and Cosmetic Act. 21 U.S. Code Sec 321(s).
  194. Federal Food, Drug, and Cosmetic Act. 21 U.S. Code Sec 571.
  195. Office of Dietary Supplements, National Institutes of Health. Dietary Supplement Health and Education Act of 1994 Public Law 103-417. Accessed February 1, 2024. https://ods.od.nih.gov/About/DSHEA_Wording.aspx
  196. FDA. Regulating animal foods with drug claims. Cited July 25, 2020. https://www.fda.gov/media/69982/download
  197. Federal Food, Drug, and Cosmetic Act. 21 U.S. Code Section 321(ff)(3)(B)
  198. FDA. FDA issues response to three citizen petitions related to CBD and dietary supplements. Accessed February 1, 2024. https://www.fda.gov/food/cfsan-constituent-updates/fda-issues-response-three-citizen-petitions-related-cbd-and-dietary-supplements
  199. FDA. FDA warns companies illegally selling CBD products. Accessed February 1, 2024. https://www.fda.gov/news-events/press-announcements/fda-warns-companies-illegally-selling-cbd-products
  200. FDA. FDA warns companies for illegally selling food and beverage products that contain CBD. Accessed February 1, 2024. https://www.fda.gov/food/cfsan-constituent-updates/fda-warns-companies-illegally-selling-food-and-beverage-products-contain-cbd
  201. FDA. Compliance & enforcement. Cited July 25, 2020. https://www.fda.gov/animal-veterinary/compliance-enforcement
  202. Vermont General Assembly S.58 Act 44 2019 May. Cited July 25, 2020. https://legislature.vermont.gov/bill/status/2020/S.58
  203. Nevada Legislature 79th Session SB 344 2017 July. Cited July 25, 2020. https://www.leg.state.nv.us/App/NELIS/REL/79th2017/Bill/5354/Overview
  204. Legislative Counsel's Digest, California AB 2215. Cited May 17, 2019. https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=201720180AB2215
  205. California Veterinary Medical Board Guidelines for Veterinarian Discussion of Cannabis within the Veterinarian-Client-Patient Relationship. Accessed February 1, 2024. https://www.vmb.ca.gov/forms_pubs/cannabis_guidelines.pdf
  206. California AB-1885. Cannabis and cannabis products: animals: veterinary medicine. Accessed February 1, 2024. https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202120220AB1885
  207. Nolen SR. Nevada veterinarians can treat patients with certain cannabis products; many questions yet to be answered about cannabinoids as a veterinary treatment. Accessed February 1, 2024. https://www.avma.org/javma-news/2021-10-01/nevada-veterinarians-can-treat-patients-certain-cannabis-products
  208. Nevada AB533. Accessed February 1, 2024. https://www.leg.state.nv.us/App/NELIS/REL/80th2019/Bill/7056/Overview
  209. Michigan HB 5085 (2019). Accessed February 1, 2024. https://www.legislature.mi.gov/(S(20sv4bsidpceqtg40og2rqb3))/mileg.aspx?page=GetObject&objectname=2019-HB-5085
  210. Florida Rule Chapter 5E-3. Accessed February 1, 2024. https://www.flrules.org/gateway/ChapterHome.asp?Chapter=5E-3
  211. South Carolina General Bill A14, R23, H3449. Accessed February 1, 2024. https://www.scstatehouse.gov/sess123_2019-2020/bills/3449.htm
  212. Vermont Bill S.58. Accessed February 1, 2024. https://legislature.vermont.gov/Documents/2024/Docs/BILLS/S-0058/S-0058%20As%20Introduced.pdf
  213. New Jersey bill A5322. Accessed February 1, 2024. https://legiscan.com/NJ/bill/A5322/2018
  214. New York State Assembly Bill A7680A. Accessed February 1, 2024. https://www.nysenate.gov/legislation/bills/2019/A7680
  215. Ohio Senate Bill 57. Accessed February 1, 2024. https://www.legislature.ohio.gov/legislation/133/sb57
  216. New York State Assembly Bill A5172. Accessed February 1, 2024. https://www.nysenate.gov/legislation/bills/2021/A5172
  217. World Health Organization. Expert Committee on Drug Dependence. Cited July 25, 2020. https://www.who.int/groups/who-expert-committee-on-drug-dependence
  218. United Nations Commission on Narcotic Drugs. Cited July 25, 2020. https://www.unodc.org/unodc/en/commissions/CND/index.html
  219. United Nations. Single Convention on Narcotic Drugs, 1961. Accessed February 1, 2024. https://www.unodc.org/pdf/convention_1961_en.pdf
  220. United Nations. Convention on Psychotropic Substances of 1971. Accessed February 1, 2024. https://www.unodc.org/pdf/convention_1971_en.pdf
  221. World Health Organization. News briefing – 40th WHO Expert Committee on Drug Dependence (ECDD). Accessed February 1, 2024. https://www.who.int/news/item/13-09-2018-40th-ecdd-news-briefing
  222. World Health Organization. Forty-first meeting of the Expert Committee on Drug Dependence. Accessed February 1, 2024. https://www.who.int/news-room/events/detail/2018/11/12/default-calendar/forty-first-meeting-of-the-expert-committee-on-drug-dependence
  223. United Nations Commission on Narcotic Drugs. WHO recommendations on cannabis and cannabis-related substances. Accessed February 1, 2024. https://www.unodc.org/documents/commissions/CND/Scheduling_Resource_Material/Cannabis/Recommendations_backdrop.pdf

⚠️ Important Disclaimer

This guide is for educational purposes only and is not intended to replace professional veterinary advice. CBD products are not FDA-approved drugs and are not intended to diagnose, treat, cure, or prevent any disease.

Always consult your veterinarian before starting any supplement, especially if your dog has a medical condition or takes medications. Individual results may vary.

Last Updated: March 2026

Continue Learning

🦴 CBD for Dog Arthritis

Deep dive into clinical studies, dosing, and what works for joint pain

Read Full Guide →

🧠 CBD for Dog Seizures

Clinical evidence, safety with medications, and realistic expectations

Read Full Guide →

😰 CBD for Dog Anxiety

Research on situational vs chronic anxiety, dosing, and what works

Read Full Guide →

🐱 CBD for Cats

Feline-specific research, CBDA absorption, and dosing guidelines

Read Full Guide →

📧 Stay Updated on CBD Research

Get new studies, dosing guides, and exclusive tips delivered to your inbox

No spam. Unsubscribe anytime. We respect your privacy.

  • Quality Assurance Guarantee

    Our promise to you

  • Visit our support center

    Expert help & advice

  • Check your order status

    Updates & tracking

  • Returns & exchanges

    All you need to know
Back to top